Pharsight

Descovy generic

Descovy is an antiretroviral drug owned by Gilead Sciences. It contains Emtricitabine and Tenofovir Alafenamide as the active ingredients. It was first approved for market use on 4th of April, 2016. Descovy holds a total of 7 patents, out of which 1 has already expired.

When will Descovy generic be available?

The generic version of Descovy is anticipated to be available after 15th February, 2033. The last patent protecting this drug is U.S. Patent number US9296769, titled 'Tenofovir alafenamide hemifumarate', which is expected to expire on the same date, thus paving the way for the potential introduction of generic versions.

Descovy uses

Descovy is primarily used in the treatment of HIV infection. It works by inhibiting the replication of the virus in the body. The two active ingredients, Emtricitabine and Tenofovir, are both antiretroviral medications that block the action of a specific enzyme that HIV requires to multiply.

Descovy patent expiration

Descovy is protected by 7 patents with Gilead Sciences as the assignee. The patent protecting Descovy from generic entry is patent number US9296769, titled 'Tenofovir alafenamide hemifumarate'. The expiry of this patent on 15th February 2033 will likely trigger the availability of Descovy generic. Below are the details of the patent:

EPO Oppostions filed on Descovy

Descovy dosage

Want to ask something?